MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design
Abstract Background Mutant peptides presented by MHC (major histocompatibility complex) Class II in cancer are important targets for cancer immunotherapy. Both animal studies and clinical trials in cancer patients showed that CD4 T cells specific to tumor-derived mutant peptides are essential for th...
Main Authors: | Weijing Cai, Dapeng Zhou, Weibo Wu, Wen Ling Tan, Jiaqian Wang, Caicun Zhou, Yanyan Lou |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-08-01
|
Series: | BMC Genomics |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12864-018-4958-5 |
Similar Items
-
Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma
by: Deng Pan, et al.
Published: (2019-11-01) -
Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy
by: Xiaomei Zhang, et al.
Published: (2019-12-01) -
Progress in Neoantigen Targeted Cancer Immunotherapies
by: Xue-Jiao Han, et al.
Published: (2020-07-01) -
An Immunophenotyping of Ovarian Cancer With Clinical and Immunological Significance
by: Kai Yang, et al.
Published: (2018-04-01) -
Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome
by: Shaokang Ma, et al.
Published: (2020-01-01)